ArticleOncology letters2025
Efficacy and safety of fruquintinib combined with immunotherapy in later-line treatment of metastatic colorectal cancer.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Current Strategies and Emerging Paradigms of Immunotherapy in Microsatellite Stable Colorectal Cancer: A Review Article.Clinical drug investigation · 2026Review
- The tumor immune microenvironment of thyroid cancer and colorectal cancer: cellular crosstalk and therapeutic implications.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), later-line treatments are limited and survival outcomes are poor. The present retrospective analysis evaluated the efficacy and safety of fruquintinib + immune checkpoint inhibitors (ICIs) in MSS/mismatch repair proficient (pMMR) mCRC, having aimed to identify effective, low-toxicity regimens for personalized treatment. The present retrospective study evaluated patients with MSS/pMMR mCRC who had failed at least two prior lines of treatment (all patients had received standard first- and second-line chemotherapy) and were treated with fruquintinib plus programmed death-1 (PD-1) (PD-1 inhibitor combination group) or programmed death-ligand 1 (PD-L1) (PD-L1 inhibitor combination group) inhibitors at the Jiangsu Cancer Hospital (Nanjing, China). Clinical characteristics were collected, and the efficacy, safety and prognostic factors of fruquintinib plus different ICIs were analyzed. A total of 78 patients (PD-1 inhibitor combination group, n=63; PD-L1 inhibitor combination group, n=15) were included. Clinical characteristics did not differ significantly between the two groups (all P>0.05). The objective response rate (7.9 vs. 20.0%; P=0.363), disease control rate (74.6 vs. 60.0%; P=0.418) and median progression-free survival (PFS; 7.0 vs. 8.3 months; P=0.14) were comparable between the groups. Similarly, no significant difference in PFS was observed between patients treated with fruquintinib plus different PD-1 inhibitors (P=0.37). Multivariate Cox regression analysis identified an Eastern Cooperative Oncology Group performance status of 1 (hazard ratio=0.28; P<0.001) as an independent prognostic factor for PFS. The most common adverse events (AEs) were hypothyroidism (31.7 vs. 26.7%), proteinuria (23.8 vs. 33.3%) and hand-foot syndrome (20.6 vs. 33.3%). No AE-related deaths occurred in either group. The present study showed that fruquintinib plus ICIs could improve PFS in MSS mCRC with manageable toxicity, but there was no survival difference between treatment with the PD-1 and PD-L1 combinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.